for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

株式会社スリー・ディー・マトリックス

7777.T

現在値

298.00JPY

変化

-13.00(-4.18%)

出来高

923,600

本日のレンジ

297.00

 - 

311.00

52週レンジ

247.00

 - 

643.00

∙ 約20分前の相場を表示しています。

適時開示

3-D Matrix says exercise of options

Oct 18 (Reuters) - 3-D Matrix Ltd <7777.T>:Says 4,823 units of its 19th series options were exercised to 482,300 shares of its common stock, from Oct. 1 to Oct. 18 .

3-D Matrix says exercise of options

Sept 19 (Reuters) - 3-D Matrix Ltd <7777.T>:Says 4,949 units of its 19th series options were exercised to 494,900 shares of its common stock, from Sept. 1 to Sept. 19 .

3-D Matrix says exercise of options

Aug 14 (Reuters) - 3-D Matrix Ltd <7777.T>:Says 4,968 units of its 19th series options were exercised to 496,800 shares of its common stock from Aug. 1 to Aug. 14 .

3-D Matrix's unit and DEMEDIC enter into a partnership agreement

May 10 (Reuters) - 3-D Matrix Ltd <7777.T>:Says its unit 3-D Matrix Europe SAS. and DEMEDIC S.A, have entered into a partnership agreement for sales and marketing of our absorbable local hemostat "PuraStat®" in Argentina on May 10.In this agreement, unit will grant a non-exclusive sales and marketing license to Demedic in Argentina .

3-D Matrix raises 885 mln yen via private placement

Nov 20 (Reuters) - 3-D Matrix Ltd <7777.T>:Says it issued 1.3 million shares and raised 885 million yen via private placement on Nov. 20.Previous news was disclosed on Nov. 1.

3-D Matrix to issue new shares to raise net amount of 835 mln yen

Nov 1 (Reuters) - 3-D Matrix Ltd <7777.T>:Says it plans to issue 1.3 million new shares to an investment limited liability partnership to raise 835 million yen (net amount) via private placement .Says payment date on Nov. 20.Says proceeds will be mainly used for R&D expenses.

3-D Matrix and National Cancer Center Japan receives joint patent on new nucleic acid medical technology

June 29 (Reuters) - 3-D Matrix Ltd <7777.T>: :* Says the company and National Cancer Center Japan have received the domestic patent on new nucleic acid medicine technology for bone cancer treatment.* Patent number is 6153932.

3-D Matrix signs license agreement in China on absorbable local hemostat

3-D Matrix Ltd <7777.T> :Says co enters into license agreement with Chinese Peptide Company Ltd, on development and sale of absorbable local hemostat products in China.

3-D Matrix obtains patent license for tissue occlusion agent in Europe

3-D Matrix Ltd <7777.T> :Says it obtains patent license for its tissue occlusion agent (PM03) in Europe, with patent publication number of EP2345433.

3-D Matrix unit signs partnership agreement regarding sales and marketing of absorbable local hemostat "PuraStat®"in Germany

3-D Matrix Ltd <7777.T> :Says unit 3-D Matrix Europe SAS entered into partnership agreement concluded with Nicolai Medizintechnik GmbH regarding sales and marketing of absorbable local hemostat "PuraStat®" in Germany.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up